Welcome to our dedicated page for Kardigan news (Ticker: KARD), a resource for investors and traders seeking the latest updates and insights on Kardigan stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kardigan's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kardigan's position in the market.
Kardigan (KARD) will present at two September 2026 healthcare investor conferences, including a webcast fireside chat.
The company will join the 2026 Cantor Global Healthcare Conference for a fireside chat on Wednesday, September 9, 2026, at 1:35 pm ET, and participate in 1x1 and small group meetings at Baird's 2026 Global Healthcare Conference on Tuesday, September 15, 2026. A live webcast and limited-time replay of the Cantor fireside chat will be available via the Investors & Media section of Kardigan’s website.
Kardigan (Nasdaq: KARD) reported second quarter 2026 results and updates on its three late-stage cardiovascular programs, danicamtiv, ataciguat and tonlamarsen. Cash, cash equivalents and investments were $660.7 million as of June 30, 2026, up from $335.5 million at year-end 2025, reflecting net proceeds from a June IPO with $460 million in aggregate gross proceeds.
Danicamtiv’s KINSHIP-DCM Phase 2b Cohort 1 enrollment has been completed and the Phase 3 portion is now enrolling, with Phase 2b topline data expected in 1H 2027. Ataciguat’s KATALYST-AV Phase 2b and tonlamarsen’s KARDINAL-ASH Phase 2 trials are ongoing, with topline data for both also targeted for 1H 2027. Q2 2026 research and development expenses rose to $56.4 million and net loss widened to $116.2 million, driven mainly by higher clinical spending and a $43.5 million change in fair value of contingent milestone liabilities.
Kardigan (Nasdaq: KARD), a clinical-stage precision cardiovascular therapeutics company, closed its initial public offering of 28,750,000 common shares, including 3,750,000 from the full underwriters’ option, at $16.00 per share.
Gross proceeds totaled $460 million before underwriting discounts and expenses, and the stock trades on the Nasdaq Global Market as KARD.
Kardigan (Nasdaq: KARD), a clinical-stage precision therapeutics company focused on cardiovascular diseases, priced its upsized IPO of 25,000,000 shares at $16 per share.
Gross proceeds are expected to be $400 million, with trading on the Nasdaq Global Market starting June 18, 2026, and closing expected June 22, 2026.